therapeutics targeting cell adhesion
Zonula works with an extensive worldwide network of highly skilled professionals with years of experience in their respective fields.
FOUNDER AND PRESIDENT
Orest Blaschuk, Ph.D., President
Dr. Blaschuk founded Zonula, a privately held biotechnology company located in Montreal, Quebec, Canada, in 2010. Dr. Blaschuk has worked in the field of cell adhesion for over three decades and has been a tenured Associate Professor on the Faulty of Medicine at McGill University since1987. Before starting Zonula, Dr. Blaschuk co-founded
Dr. Blaschuk founded Zonula, a privately held biotechnology company located in Montreal, Quebec, Canada, in 2010. Dr. Blaschuk has worked in the field of cell adhesion for over three decades and has been a tenured Associate Professor on the Faulty of Medicine at McGill University since1987. Before starting Zonula, Dr. Blaschuk co-founded Adherex Incorporated in 1996, a publicly traded, McGill spin-off oncology company, where he served as Chief Scientist (1996-2005) and consultant (2005-2009). Adherex developed anti-cancer drugs targeting cell adhesion molecules (i.e. biological glues) based on intellectual property generated in Dr. Blaschuk's laboratory at McGill University. The Adherex drug ADH-1 (a peptide targeting the cell adhesion molecule, N-cadherin) reached Phase II clinical trials as an anti-cancer agent and was given orphan drug status by the FDA for the treatment of melanoma. Dr. Blaschuk thus has proven expertise in drug discovery and development from the laboratory to the clinic. Dr. Blaschuk has authored 76 scientific journals and is an inventor on 50 U.S. patents.